Publication:
Adverse cardiac events related to hydroxychloroquine prophylaxis and treatment of COVID-19

Placeholder

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Zengin, Rehile
Sarıkaya, Zeynep Tuğçe
Karadağ, Nalan
Çuhadaroğlu, Çağlar
Kocagöz, Sesin

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Coronavirus disease 2019 (COVID-19) was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. The disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). The measures to contain the spread of the disease such as social-distancing, hand hygiene, contact tracing, and isolation of persons suspected or confirmed to have the infection have been considered to be largely effective. No specific drugs for COVID-19 have been proven to be effective currently for either prophylaxis or treatment. However, hydroxychloroquine (HCQ) was suggested as one of the choices of the drug, despite the lack of evidence-based information. We present three case reports of cardiovascular adverse effects, with respect to its propensity to cause QT interval prolongation and potentially serious cardiac arrhythmias.

Source

Publisher

DOC Design and Informatics

Subject

Covid-19, Cardiac, Kovid-19, Kardiyak

Citation

Has Part

Source

Infectious Diseases and Clinical Microbiology (Online)

Book Series Title

Edition

DOI

10.36519/idcm.2020.0012

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details